Edwards, Abbott Spar Over Valve Repair Patents
Executive Summary
A Delaware court sided with Abbott over Edwards in a pretrial hearing on terminology to be used in a patent dispute concerning transcatheter mitral valve repair device technology.
You may also be interested in...
Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark
Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.
Patent Board Rejects Edwards’ Heart Valve Claim-Review Request
The US Patent Office has rejected a request by Edwards Lifesciences to review an Abbott patent on heart-valve technology, which could establish the patent as a key part of Abbott Laboratories’ arguments in a larger ongoing intellectual property case.
Edwards’ Pascal Improves Mitral Regurgitation In Early Trial Results
One-month results from the CLASP trial, presented at the German Cardiology Meeting (DGK), show Edwards’ Pascal mitral valve repair device reduces mitral regurgitation in heart failure patients with moderate to severe mitral regurgitation.